NASDAQ:DYAI Dyadic International (DYAI) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free DYAI Stock Alerts $1.50 +0.01 (+0.67%) (As of 10:51 AM ET) Add Compare Share Share Today's Range$1.50▼$1.5050-Day Range$1.29▼$1.8752-Week Range$1.19▼$2.40Volume527 shsAverage Volume21,812 shsMarket Capitalization$43.46 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Dyadic International alerts: Email Address Dyadic International MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside297.4% Upside$6.00 Price TargetShort InterestHealthy0.90% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.44) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.27 out of 5 starsMedical Sector730th out of 909 stocksBiological Products, Except Diagnostic Industry127th out of 156 stocks 3.5 Analyst's Opinion Consensus RatingDyadic International has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageDyadic International has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.90% of the float of Dyadic International has been sold short.Short Interest Ratio / Days to CoverDyadic International has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Dyadic International has recently decreased by 2.47%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldDyadic International does not currently pay a dividend.Dividend GrowthDyadic International does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DYAI. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 2 people have searched for DYAI on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows1 people have added Dyadic International to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dyadic International insiders have not sold or bought any company stock.Percentage Held by Insiders27.30% of the stock of Dyadic International is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.95% of the stock of Dyadic International is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Dyadic International are expected to decrease in the coming year, from ($0.44) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyadic International is -6.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyadic International is -6.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyadic International has a P/B Ratio of 7.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Dyadic International Stock (NASDAQ:DYAI)Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Read More DYAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DYAI Stock News HeadlinesApril 1, 2024 | msn.comDYAI: Capital Raise to Accelerate Near Term Revenue GrowthApril 1, 2024 | insidermonkey.comDyadic International, Inc. (NASDAQ:DYAI) Q4 2023 Earnings Call TranscriptApril 24, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.March 30, 2024 | seekingalpha.comDyadic International, Inc. (DYAI) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finance.yahoo.comQ4 2023 Dyadic International Inc Earnings CallMarch 28, 2024 | benzinga.comRecap: Dyadic International Q4 EarningsMarch 28, 2024 | globenewswire.comDyadic Reports 2023 Full Year Results and Recent Company ProgressMarch 28, 2024 | globenewswire.comDyadic Announces Change in Board and Management Leadership RolesApril 24, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.March 27, 2024 | globenewswire.comDyadic to Attend Industry Events in AprilMarch 26, 2024 | globenewswire.comDyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature CommunicationsMarch 21, 2024 | globenewswire.comDyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, CaliforniaMarch 14, 2024 | globenewswire.comDyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024March 11, 2024 | finance.yahoo.comDyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and CommercializationMarch 11, 2024 | globenewswire.comCORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and CommercializationMarch 11, 2024 | globenewswire.comDyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and CommercializationMarch 1, 2024 | globenewswire.comDyadic to Attend Industry Events in MarchFebruary 29, 2024 | ca.finance.yahoo.comDYAI Aug 2024 2.500 callFebruary 29, 2024 | ca.finance.yahoo.comDYAI Apr 2024 2.500 callFebruary 28, 2024 | msn.comDyadic announces strategic partnership agreement to develop rabies vaccinesFebruary 28, 2024 | globenewswire.comDyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production PlatformFebruary 23, 2024 | globenewswire.comDyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease SolutionsFebruary 21, 2024 | finance.yahoo.comDyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease SolutionsFebruary 21, 2024 | finance.yahoo.comDyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease SolutionsFebruary 21, 2024 | globenewswire.comDyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease SolutionsFebruary 20, 2024 | finance.yahoo.comDYAI: Catching Up With DyadicFebruary 6, 2024 | msn.comDyadic signs R&D agreement with global biopharmaceutical companySee More Headlines Receive DYAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyadic International and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/24/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:DYAI CUSIPN/A CIK1213809 Webwww.dyadic.com Phone(561) 743-8333Fax561-743-8343Employees7Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+297.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,800,000.00 Net Margins-234.39% Pretax Margin-234.39% Return on Equity-81.57% Return on Assets-65.71% Debt Debt-to-Equity RatioN/A Current Ratio3.58 Quick Ratio3.58 Sales & Book Value Annual Sales$2.90 million Price / Sales15.08 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book7.55Miscellaneous Outstanding Shares28,970,000Free Float21,064,000Market Cap$43.74 million OptionableOptionable Beta0.60 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Mark A. Emalfarb (Age 68)Founder, CEO, President & Director Comp: $636.61kMs. Ping Wang Rawson CPA (Age 48)M.B.A., Chief Financial Officer Comp: $279.07kMr. Doug Pace B.A.Executive Vice President of Business DevelopmentMs. Ana Gómez RodriguezSecretary of the BoardKey CompetitorsNKGen BiotechNYSE:NKGNSAB BiotherapeuticsNASDAQ:SABSOKYO PharmaNASDAQ:OKYOCidara TherapeuticsNASDAQ:CDTXQuince TherapeuticsNASDAQ:QNCXView All CompetitorsInstitutional OwnershipSimplex Trading LLCBought 100 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions DYAI Stock Analysis - Frequently Asked Questions Should I buy or sell Dyadic International stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dyadic International in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DYAI shares. View DYAI analyst ratings or view top-rated stocks. What is Dyadic International's stock price target for 2024? 1 Wall Street analysts have issued 12 month price objectives for Dyadic International's stock. Their DYAI share price targets range from $6.00 to $6.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 297.4% from the stock's current price. View analysts price targets for DYAI or view top-rated stocks among Wall Street analysts. How have DYAI shares performed in 2024? Dyadic International's stock was trading at $1.61 at the start of the year. Since then, DYAI shares have decreased by 6.2% and is now trading at $1.51. View the best growth stocks for 2024 here. When is Dyadic International's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our DYAI earnings forecast. How were Dyadic International's earnings last quarter? Dyadic International, Inc. (NASDAQ:DYAI) posted its earnings results on Thursday, March, 28th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.01. The biotechnology company had revenue of $0.69 million for the quarter, compared to analysts' expectations of $0.80 million. Dyadic International had a negative net margin of 234.39% and a negative trailing twelve-month return on equity of 81.57%. What other stocks do shareholders of Dyadic International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dyadic International investors own include Silvercorp Metals (SVM), Endeavour Silver (EXK), Hecla Mining (HL), Pfizer (PFE), Advanced Micro Devices (AMD), Endeavour Silver (EDR), Mandalay Resources (MND), Alibaba Group (BABA) and Chimerix (CMRX). How do I buy shares of Dyadic International? Shares of DYAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DYAI) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingPrepare for a recession unlike any otherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyadic International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
